Literature DB >> 15804924

Years of severe and isolated amnesia can precede the development of dementia in early-onset Alzheimer's disease.

Jette Stokholm1, Oda Jakobsen, Justyna M Czarna, Henrik V Mortensen, Gunhild Waldemar.   

Abstract

A young patient with a severe and isolated memory disorder, meeting the criteria for MCI, was followed for a period of 8 years. His overall functional level remained stable with a CDR-score at 0.5 until the last year when it dropped to 1.0. Neuropsychological testing showed severe memory deficits but otherwise normal cognitive functions. Only minimal progression was measured; however, the last testing showed impaired abstraction and executive functioning as well as discrete problems generating names of objects and people. Neuroimaging, with MRI and SPECT, was consistent with a progressive degenerative disorder, and cerebrospinal fluid levels of beta-amyloid 1-42, tau protein, and phosphorylated tau protein were characteristic of Alzheimer's disease (AD). We argue that this is a case of prodromal AD, which illustrates an extreme version of the normal course with respect to slow progression of the disease and severity of amnesia early in the course.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804924     DOI: 10.1080/13554790490896965

Source DB:  PubMed          Journal:  Neurocase        ISSN: 1355-4794            Impact factor:   0.881


  2 in total

1.  Discriminative and predictive power of an informant report in mild cognitive impairment.

Authors:  V Isella; L Villa; A Russo; R Regazzoni; C Ferrarese; I M Appollonio
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

2.  Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study.

Authors:  P J Visser; F R J Verhey; M Boada; R Bullock; P P De Deyn; G B Frisoni; L Frolich; H Hampel; J Jolles; R Jones; L Minthon; F Nobili; M Olde Rikkert; P-J Ousset; A-S Rigaud; P Scheltens; H Soininen; L Spiru; J Touchon; M Tsolaki; B Vellas; L-O Wahlund; G Wilcock; B Winblad
Journal:  Neuroepidemiology       Date:  2008-06-02       Impact factor: 3.282

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.